Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients

MonitoringEGFRT790M with plasma DNA from lung cancer patients in a prospective observational study

(2016) Naoko Sueoka-Aragane et al.   CANCER SCIENCE

Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances

(2016) Gustaw Lech   WORLD JOURNAL OF GASTROENTEROLOGY

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer

(2015) S. Arena et al.   CLINICAL CANCER RESEARCH

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial

(2015) Josep Tabernero et al.   LANCET ONCOLOGY

Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers

(2015) Sandra Misale et al.   Nature Communications

Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study

(2015) Takayuki Yoshino et al.   EBioMedicine

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA

(2014) Alain R Thierry et al.   NATURE MEDICINE

Correlation between Plasma DNA and Tumor Status in an Animal Model

(2014) Naoko Sueoka-Aragane et al.   PLoS One

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution

(2014) S. Misale et al.   Cancer Discovery

Increased TGF-  as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR-MET Interaction and Activation of MET Signaling in Colon Cancer Cells

(2013) T. Troiani et al.   CLINICAL CANCER RESEARCH

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

(2013) Jean-Yves Douillard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intratumor Heterogeneity: Evolution through Space and Time

(2012) C. Swanton   CANCER RESEARCH

Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan

(2012) K.-L. G. Spindler et al.   CLINICAL CANCER RESEARCH

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA

(2012) Tomomi Nakamura et al.   Journal of Thoracic Oncology

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA

(2011) Tomomi Nakamura et al.   Journal of Thoracic Oncology

Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis

(2010) Mohamed Bouchahda et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review

(2010) Jolien Tol et al.   CLINICAL THERAPEUTICS

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

(2010) S. A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE